Skip to content


Volume 15 Supplement 3

Sepsis 2011

  • Poster presentation
  • Open Access

Clinical and biological effects of high-dose sodium selenite, continuously administered in septic shock

  • 1,
  • 2,
  • 3,
  • 4,
  • 5,
  • 6,
  • 7,
  • 4,
  • 3,
  • 8,
  • 1 and
  • 8
Critical Care201115 (Suppl 3) :P16

  • Published:


  • Selenium
  • Septic Shock
  • Selenite
  • Procalcitonin
  • Sodium Selenite


Sodium selenite (Na2SeO3) has been proposed as an early treatment of septic shock with discrepant results [13]. Beneficial action is mainly believed through improvement of major antioxidant selenoenzymes, but could on the contrary be related to a therapeutic oxidant action reducing activity of hyperactivated circulating phagocytic cells [4]. It has been suggested that the absence of beneficial effect of high-dose Na2SeO3 continuously administered [2] might be related to toxicity, especially on the lung, of too much selenium (Se) as mentioned in recent parenteral nutrition guidelines in intensive care [5]. On additional clinical and biological data, our purpose was to assess if there was argument for Na2SeO3 toxicity, especially on the lung, under continuous administration of high-dose Na2SeO3 in the SERENITE study.


In a randomized, double-blind multicenter study performed in 60 septic shock patients [2], the efficacy and tolerance of Na2SeO3 (4 mg Se on day 1 (D1), then 1 mg/day during 9 days or placebo) were evaluated on all components of the SOFA score measured daily, infection rate, and plasma Se, selenoprotein-P (Sel-P), glutathione peroxidase (GPx), lipid peroxidation, cytokines, and procalcitonin measured at D0, D4, D7, D10 and D14.


No deleterious effect of Na2SeO3 especially on the lung was observed for any clinical or biological variables. PaO2/FiO2 was strictly identical between groups (Table 1). As compared with placebo, mean time occurrences of infections were delayed in the treated group (18 ± 24 days vs. 34 ± 28 days, respectively; P < 0.0001). Plasma Se, Sel-P and GPx concentrations were increased at D4 in the treated group, achieving the high reference value for the plasma Se concentration (Figure 1).
Table 1

PaO2/FiO2 according to group and time











20 ± 15

23 ± 12

24 ± 10

25 ± 14

26 ± 11

30 ± 13

28 ± 15


22 ± 13

21 ± 11

25 ± 13

26 ± 11

28 ± 14

33 ± 17

36 ± 17

P value








Data presented as mean ± SD (KPa).

Figure 1
Figure 1

Plasma Se concentration according to groups and time. Data presented as mean ± SD (μmol/l). Reference value for plasma Se concentration: 1 ± 0.15 μmol/l. Treated group indicated in blue and nontreated in green.


Continuous administration of high doses of Na2SeO3 (4 mg Se D1) did not induce any deleterious effect in septic shock patients. We did not observe a beneficial effect, contrasting with a comparable study administering Na2SeO3 in bolus, potentially more toxic [1]. In agreement with results obtained on a peritonitis sheep model [6], our data support a therapeutic oxidant action of Na2SeO3, opening a new field in septic shock treatment based on oxidant selenocompounds.



The authors thank all the investigators, biochemists, pharmacists and clinical research team involved in the SERENITE Study, the Minister of Health for financing, and Meaux Hospital as promotor. XF is the co-inventor with DV of patent FR 98 10889, PCT N°FR 99/02.66 (delivered: US 6,844,012 B1, Au 760 534; EP 1107767), and has ownership of the corresponding patent. XF is the main shareholder of a small start-up named SÉRÉNITÉ-Forceville devoted to early diagnosis and treatment of septic shock especially by selenocompounds.

Authors’ Affiliations

Réanimation Polyvalente, CH de Meaux, France
Biochimie A, CHU St Louis, Paris, France
Toxicology and Carcinogenesis, Nofer Institute, Lodz, Poland
Biochimie métabolique et cellulaire, CHU Bichat, Paris, France
Chimie pharmaceutique organique, Université Libre de Bruxelles, Belgium
Réanimation CHU Poincaré, Garches, France
Biochimie CH de Meaux, France
Recherche - Santé Publique, CHU Pontchaillou, CIC Inserm 0203,, Rennes, France


  1. Angstwurm MW, Engelmann L, Zimmermann T, Lehmann C, Spes CH, Abel P, Strauss R, Meier-Hellmann A, Insel R, Radke J, et al.: Selenium in Intensive Care (SIC): results of a prospective randomized, placebo-controlled, multiple-center study in patients with severe systemic inflammatory response syndrome, sepsis, and septic shock. Crit Care Med 2007, 35: 118-126. 10.1097/01.CCM.0000251124.83436.0EView ArticlePubMedGoogle Scholar
  2. Forceville X, Laviolle B, Annane D, Vitoux D, Bleichner G, Korach JM, Cantais E, Georges H, Soubirou JL, Combes A, et al.: Effects of high doses of selenium, as sodium selenite, in septic shock: a placebo-controlled, randomized, double-blind, phase II study. Crit Care 2007, 11: R73. 10.1186/cc5960PubMed CentralView ArticlePubMedGoogle Scholar
  3. Vincent JL, Forceville X: Critically elucidating the role of selenium. Curr Opin Anesthesiol 2008, 21: 148-154. 10.1097/ACO.0b013e3282f49afeView ArticleGoogle Scholar
  4. Forceville X: Seleno-enzymes and seleno-compounds: the two faces of selenium. Crit Care 2006, 10: 180. 10.1186/cc5109PubMed CentralView ArticlePubMedGoogle Scholar
  5. Singer P, Berger MM, Van den Berghe G, Biolo G, Calder P, Forbes A, Griffiths R, Kreyman G, Leverve X, Pichard C, et al.: ESPEN Guidelines on parenteral nutrition: intensive care. Clin Nutr 2009, 28: 387-400. 10.1016/j.clnu.2009.04.024View ArticlePubMedGoogle Scholar
  6. Wang Z, Forceville X, Van Antwerpen P, Piagnerelli M, Ahishakiye D, Macours P, De Backer D, Neve J, Vincent JL: A large-bolus injection, but not continuous infusion of sodium selenite improves outcome in peritonitis. Shock 2009, 32: 140-146. 10.1097/SHK.0b013e318193c35dView ArticlePubMedGoogle Scholar


© Forceville et al. 2011

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.